http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
학생논문 : 국내 배출권거래제 설계에 관한 검토: 국제배출권시장과의 정합성을 중심으로
백종현 ( Jong Hyun Paik ) 연세대학교 법학연구원 글로벌비즈니스와 법센터 2009 연세 글로벌 비즈니스 법학연구 Vol.1 No.1
작년 12월 국회에서 저탄소녹색성장기본법이 가결되었다. 동법 제46조는 총량제한(Cap & Trade) 방식의 배출권 거래제의 근거규정으로서, 이제 국내에서도 EU가 지난 2005년부터 시행해온 Cap & Trade 방식의 배출권 거래제를 시행할 수 있는 근거법이 제정된 것이다. 그러나 이와 같은 법안 마련에도 불구하고, 기업들에게 직접 온실가스 배출량을 할당함으로써 초과 배출한 범위에 대한 부족배출권과 배출할당량에 미달하여 발생한 잉여배출권을 해당 기업들이 시장에서 사고 팔수 있도록 하는 배출권거래제의 시행을 위한 시장인프라의 준비가 아직 미흡한 것이 사실이다. 따라서 동법이 규정하고 있는 총량제한 배출권 거래제를 본격적으로 시행하기 위해서는 배출권 거래소와 등록소(Registry)와 같은 시장인프라의 구축이 선결과제라 할 것이다. 또한 시장인프라의 구축과 관련하여 배출권의 법적 성격을 명확히 하여 거래안전을 도모할 필요가 있다. 배출권의 법적 성격을 고려함에 있어서는 배출권 유통상의 유동성위험을 최소화하기 위해 배출권이 자본시장에서 거래될 수 있는 방향에서 검토되어야 할 것이며, 총량제한방식을 선도입한 국가들의 예를 참조할 필요가 있을 것이다. The National Assembly passed the “Basic Act on Low Carbon Green Growth” last December. According to the Article 46(1) of the Act, Korean government is able to operate the emission trading scheme (ETS) in order to reduce GHGs. However, despite this legal ground to support Korea`s own ETS (K-ETS), the market infrastructure is not prepared adequately for emissions trading in Korea. Therefore, it is necessary for Korea to strategically learn and adopt other countries` example to establish the emissions trading market. It also needs to consider many legal and economic factors such as legal nature of the emission permits in terms of designing K-ETS in a successful way.
Etretinate 와 Methotrexate로 치유된 소아형 범발성 농포성 건선
백종현(Jong Hyun Paik),박필성(Pill Sung Park),최영자(Young Ja Choi),성호석(Ho Suk Sung) 대한피부과학회 1989 대한피부과학회지 Vol.27 No.1
A case of generalized pustular psoriasis in a 12 year-old girl is described. She had generalized pustular eruptions on erythematous base, presenting lake of pus, yellowish brown crusts and denudation associated with high fever and chills. With the administration of oral etretinate at a dose of 0.8mg/kg/day for 1 week, rapid and dramatic remission was achieved. About 3 months after her discharge, there developed another wave of new pustules with fever. She was again placed on etretinate therapy. However, there was no expected response as before with developing new pustules continuously. At that time, we tried combination therapy with etretinate and methotrexate. the pustules and erythema began to remit, with eventual clearing of the skin in 6 weeks.
백종현(Jong Hyun Paik),이무형(Mu Hyoung Lee) 대한피부과학회 2000 대한피부과학회지 Vol.38 No.10
Background:Arbutin is a glycosylated hydroquinone found at high concentration in certain plants capable of surviving extreme and sustained dehydration. It has been suggested as an inhibitory compound of melanogenesis. Objective:The purpose of this study was to investigate the effect of arbutin on melanogenesis in cultured human melanocytes and to evaluate the effectiveness of arbutin in patients with melasma. Methods:I. In vitro study:we examine the cell number, SRB assay, tyrosinase activity, and melanin contents of cultured human melanocytes in control(absence of arbutin) and experimental groups (presence of 10-5 M, 10-4 M, and 10-3 M arbutin). II. In vivo study:6 patients with melasma applied a 3 % arbutin solution twice daily for 8 weeks. Clinical response to treatment was evaluated by patients' subjective assessment and MASI(Melasma Area and Severity Index) score after 8 weeks of treatment. Results:I. In vitro study 1. The number of melanocytes was decreased in groups treated with 10-5 M, 10-4 M, 10-3 M arbutin for 2 days and 10-4 M, 10-3 M arbutin for 7 days. 2. On SRB assay, the proliferation of melanocytes was decreased in groups treated with 10-5 M, 10-4 M, 10-3 M arbutin for 2 days and for 7 days. 3. Tyrosinase activity was decreased in groups treated with 10-4 M, 10-3 M arbutin for 2 days and 10-5 M, 10-4 M, 10-3 M arbutin for 7 days. 4. The melanin contents were decreased in group treated with 10-3 M arbutin for 7 days. II. In vivo study 1. On patients'subjective assessment, one showed moderate improvement, one showed mild improvement, and the other four showed no change. 2. On MASI score, there was less than 10% improvement in all 6 patients. 3. Side effects were not found in all 6 patients.Conclusion:Although arbutin showed an inhibitory effect on cell proliferation, tyrosinase activity, and melanin synthesis in cultured human melanocytes, there was no significant effect of depigmentation in the patients with melasma. (Korean J Dermatol 2000;38(10):1303~1308)